These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36167613)

  • 1. Cryopreservation of apheresis platelets treated with riboflavin and UV light.
    Kutac D; Bohonek M; Landova L; Staskova E; Blahutova M; Malikova I; Slouf M; Horacek JM; Stansbury LG; Hess JR; Seghatchian J
    Transfus Apher Sci; 2023 Apr; 62(2):103580. PubMed ID: 36167613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pre-freeze pathogen reduction with riboflavin and UV light on red cells stored post-thaw in AS-3 additive solution.
    Kutac D; Bohonek M; Landova L; Staskova E; Blahutova M; Lovecky J; Horacek JM; Stansbury LG; Hess JR
    Transfusion; 2023 May; 63(5):1067-1073. PubMed ID: 36938976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience.
    Lachert E; Kubis J; Antoniewicz-Papis J; Rosiek A; Woźniak J; Piotrowski D; Przybylska Z; Mikołowska A; Marschner S; Łętowska M
    Adv Clin Exp Med; 2018 Jun; 27(6):765-772. PubMed ID: 29877637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemostatic profile of riboflavin-treated apheresis platelet concentrates.
    Petrou E; Nikolopoulos GK; Kriebardis AG; Pantavou K; Loukopoulou E; Tsantes AG; Georgatzakou HT; Maratou E; Rapti E; Mellou S; Kokoris S; Gialeraki A; Tsantes AE
    Blood Transfus; 2022 May; 20(3):223-234. PubMed ID: 34059193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
    Picker SM; Steisel A; Gathof BS
    Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryopreservation of platelets treated with riboflavin and UV light and stored at -80°C for 1 year.
    Jimenez-Marco T; Ballester-Servera C; Quetglas-Oliver M; Morell-Garcia D; Torres-Reverte N; Bautista-Gili AM; Serra-Ramon N; Girona-Llobera E
    Transfusion; 2021 Apr; 61(4):1235-1246. PubMed ID: 33694171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
    Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
    Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
    Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
    Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro characteristics and in vivo platelet quality of whole blood treated with riboflavin and UVA/UVB light and stored for 24 hours at room temperature.
    Lunde THF; Hartson L; Bailey SL; Hervig TA
    Transfusion; 2021 Jul; 61 Suppl 1():S101-S110. PubMed ID: 34269459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.
    Picker SM; Tauszig ME; Gathof BS
    Transfusion; 2012 Mar; 52(3):510-6. PubMed ID: 21981030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS.
    Janetzko K; Hinz K; Marschner S; Goodrich R; Klüter H
    Vox Sang; 2009 Oct; 97(3):234-9. PubMed ID: 19790298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
    Picker SM; Oustianskaia L; Schneider V; Gathof BS
    Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
    Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
    Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
    van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
    Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products.
    Keil SD; Saakadze N; Bowen R; Newman JL; Karatela S; Gordy P; Marschner S; Roback J; Hillyer CD
    Transfusion; 2015 Apr; 55(4):858-63. PubMed ID: 25438832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of use of riboflavin and ultraviolet light for pathogen inactivation on quality of platelet concentrates].
    Stanojković Z; Antić A; Stojanović M
    Vojnosanit Pregl; 2011 Jun; 68(6):489-94. PubMed ID: 21818915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Freezing of Apheresis Platelet Concentrates in 6% Dimethyl Sulfoxide: The First Preliminary Study in Turkey.
    Yılmaz S; Çetinkaya RA; Eker İ; Ünlü A; Uyanık M; Tapan S; Pekoğlu A; Pekel A; Erkmen B; Muşabak U; Yılmaz S; Avcı İY; Avcu F; Kürekçi E; Eyigün CP
    Turk J Haematol; 2016 Mar; 33(1):28-33. PubMed ID: 25912150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days.
    Kaplan A; Lindgren B; Marschner S; Aznar M; Zalba S; Sánchez P; Ayape ML; Olavarría E; Antelo ML
    Transfus Apher Sci; 2016 Apr; 54(2):248-52. PubMed ID: 26345109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies.
    Picker SM; Schneider V; Gathof BS
    Transfusion; 2009 Jun; 49(6):1224-32. PubMed ID: 19220821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma.
    Smith J; Rock G
    Transfusion; 2010 Apr; 50(4):926-31. PubMed ID: 20051060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.